KLARINGSRAPPORT - Ugeskrift for Læger

KLARINGSRAPPORT 2319. LITTERATUR1. McGlashan TH. Early detection and intervention in schizophrenia:Editor’s introduction. Schizophr Bull 1996; 22: 197-9.2. McGlashan TH, Johannessen JA. Early detection and interventionwith schizophrenia: rationale. Schizophr Bull 1996; 22: 201-22.3. Wyatt RJ, Green MF, Tuma AH. Long-term morbidity associatedwith delayed treatment of first admission schizophrenic patients: are-analysis of the Camarillo State Hospital data. Psychol Med 1997;27: 261-8.4. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychoticdrugs: a critical analysis. Psychopharmacology 1996;124: 2-34.5. Kopala LC, Kimberley PG, Honer WG. Extrapyramidal signs andclinical symptoms in first-episode schizophrenia: response to lowdoserisperidone. J Clin Psychopharmacol 1997; 17: 308-13.6. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia.Am J Psychiatry 1994; 151: 825-35.7. Umbricht D, Kane JM. Risperidone: efficacy and safety. SchizophreniaBull 1995; 21: 593-606.8. Sanchez C, Arnt J, Dragsted N, Hystel J, Lembøj HL, Meier E etal. Neurochemical and in vivo pharmacological profile of sertindole,a limbic-selective neuroleptic compound. Drug Dev Res1991; 22: 239-50.9. Skarsfeldt T. Differential effects of repeated administration ofnovel antipsychotic drugs on the activity of midbrain dopamineneurons in the rat. Eur J Pharmacol 1995; 281: 289-94.10. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine,a novel atypical antipsychotic, on A9 and A10 dopamineneuron. Neuropsychopharmacology 1996; 14: 97-104.11. Van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, SebreeTB. A randomized, controlled, dose-ranging trial of sertindole inpatients with schizophrenia. Psychopharmacology 1996; 124: 168-75.12. Kufferle B, Tauscher J, Asenbaum S, Vesely C, Podreka I, BruckeT et al. IBZM SPECT imaging of striatal dopamin-2 receptors inpscyhotic patients treated with the novel antipsychotic substancequetiapine in comparison to clozapine and haloperidol. Pscychopharmacology1997; 133: 323-8.13. Philbrick KL, Rummans TA. Malignant catatonia. J NeuropsychiatryClin Neurosci 1994; 6: 1-13.14. Mann SC, Caroff SN, Bleier HR, Welz WKR, Kling MA, HayashidiaM. Lethal catatonia. Am J Psychiatry 1986; 143: 1374-81.15. Rohland BM, Carroll BT, Jacoby RG. ECT in the treatment of catatonicsyndrome. J Affect Disord 1993; 29: 255-61.16. Fleischhacker WW, Unterweger B, Kane JM, Hinterhuber H. Theneuroleptic malignant syndrome and its differentiation from lethalcatatonia. Acta Psychiatr Scand 1990; 81: 3-5.17. White DAC. Catatonia and the neuroleptic malignant syndrome –a single entity? Br J Psychiatry 1992; 161: 558-60.18. Licht RW. Mani. I lyset af psykiatriens nye sprog. MånedsskrPrakt Lægegern, Februar 1997; 202-12.19. Lublin H, Mellergaard M, eds. Clozapin – nyere forskning og rekommandationer.Nord J Psychiatry 1997; suppl 40 (51): 1-80.20. Abdel-Hamid HA, Abdel-Rahman MS, Abdel-Rahman SA. Teratogeniceffect of diphenylhydantoin and/or fluphenazine in mice. JAppl Toxicol 1996; 16: 221-5.21. Gill TS, Guram MS, Geber WF. Haloperidol teratogenicity in thefetal hamster. Dev Pharmacol Ther 1982; 4: 1-5.22. Kola I, Folb PI. Chlorpromazine inhibits the mitotic index, cellnumber, and formation of mouse blastocysts, and delays implantationof CBA mouse embryos. J Reprod Fertil 1986; 76: 527-36.23. Altshuler LL, Szuba MP. Course of psychiatric disorders in pregnancy.Neural Clin 1994; 12: 613-35.24. Godet PF, Marie-Cardine M. Neuroleptics, schizophrenia andpregnancy. Epidemiological and teratologic study. Encephale 1991;17: 543-7.25. McCullar FW, Heggeness L. Limb malformations following maternaluse of haloperidol. JAMA 1975; 231: 62-4.26. Sitland-Marken PA, Rickman LA, Wells BG, Mabie WC. Pharmacologicmanagement of acute mania in pregnancy. J Clin Psychopharmacol1989; 9: 78-87.27. Handal M, Matheson I, Bechensteen AG, Lindemann R. Antipsykotikaog gravide. En kasuistikk. Tidsskr Nor Lægeforen 1995;115: 2539-40.28. Abdul-Karim RW. Drugs during pregnancy – clinical perspectives.Philadelphia: George F. Stickley Company, 1981: 91-101.29. Cohen LS. Psychotropic drugs use in pregnancy. Hosp CommunityPsychiatry 1989; 40: 566-7.30. Goldberg HL. Psychotropic drugs in pregnancy and lactation. JPsychiatry Med 1994; 24: 129-49.31. Guze BH, Guze PA. Psychotropic medication use during pregnancy.West J Med 1989; 151: 296-8.32. Kerns LL. Treatment of mental disorders in pregnancy – a reviewof psychotropic drug risks and benefits. J Nerv Mental Dis 1986;174: 652-9.33. Kerns LL. The clinical dilemma of psychotropic drugs use duringpregnancy. West J Med 1989: 151: 321.34. Mortola J. The use of psychotropic agents in pregnancy and lactation.Psychiatr Clin North Am 1989; 12: 69-87.35. Rieder RO, Rosenthal D, Blumenthal H. The offspring of schizophrenics;fetal and neonatal deaths. Arch Gen Psychiatry 1975; 32:200-11.36. McBride WG, Hicks LJ. Acetylcholine and choline levels in rabbitfetuses exposed to anticholinergics. Int J Dev Neurosci 1987; 5:117-25.37. Miller LJ. Clinical strategies for the use of psychotropic drugs duringpregnancy. Psychiatry Med 1991; 9: 275-98.38. Yoshida K, Smith B, Craggs M, Kumar R. Neuroleptic drugs inbreast-milk: a study of pharmacokinetics and of possible adverseeffects in breast-fed infants. Psychol Med 1998; 28: 81-91.39. Ereshefsky L. Pharmacokinetics and drug interaction: update fornew antipsychotics. J Clin Psychiatry 1996; 57 (suppl 11): 12-25.40. Jackson CW, Markowitz JS, Brewerton TD. Delirium associatedwith clozapine and benzodiazepine combinations. Ann Clin Psychiatry1995; 7: 139-41.41. Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, VolpicelliSA, Flood JG. Serum levels of clozapine and norclozapine inpatients treated with selective serotonin reuptake inhibitors. Am JPsychiatry 1996; 153: 820-2.42. Peacock L, Gerlach J. Antipsychotic-induced side effects related toreceptor afffinity, I: Csernansky J. ed. Antpscyhotics – handbookof experimental pharmacology. Berlin: Springer, 1996; 120.43. Kerwin R, Taylor D. New antipsychotics. A review of their currentstatus and clinical potential. CNS Drugs 1996; 6: 71-82.44. Richelson E. Preclinical pharmacology of neuroleptics: focus on newgeneration compounds. J Clin Psychiatry 1996; 57 (suppl 11): 4-11.45. Casey DE. Neuroleptic-induced acute extrapyramidal symdromesand tardive dyskinesia. I: Hirsch S, Weinberger DR, eds. Schizophrenia.Oxford: Blackwell, 1995: 546-65.46. Kane JM, Jeste DV, Barnes TRE, Casey DE, Cole JO, Davis JM etal. Tardive dyskinesia: a task force report of the American PsychiatricAssociation. Washington, DC: American Psychiatric Press,1992.47. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neurolepticwithdrawal in schizophrenic patients: a review of the literature.Arch Gen Psychiatry 1995; 52: 173-88.48. Fenton WS, Wyatt RJ, McGlashan TH. Risk factors for spontaneousdyskinesia in schizophrenia. Arch Gen Psychiatry 1994; 51:643-50.49. Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, WoernerM et al. Prevalence and clinical correlates of extrapyramidalsign and spontaneous dyskinesia in never-medicated schizophrenicpatients. Am J Psychiatry 1995; 152: 1724-9.50. Glenthøj BY, Hemmingsen R. Dopaminergic sensitization: implicationsfor the pathogenesis of schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 1997; 21: 23-46.51. Glenthøj B, Hemmingsen R. Transmitter dysfunction at variousstages of process schizophrenia. Acta Psychiatr Scand, Suppl 1998(i trykken).52. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, SummerfeltA et al. Effects of clozapine on positive and negative symptomsin outpatients with schizophrenia. Am J Psychiatry 1994; 15:20-6.53. Davis JM, Barter JT, Kane JM. Antipsychotic drugs. I: Kaplan HI,Sadock BJ, eds. Comprehensive textbook of psychiatry. 5th Ed.Baltimore: Williams & Wilkins, 1989; 2: 1591-626.54. Dencker SJ, Giös I, Mårtensson E, Nordén T, Nyberg G, PerssonR et al. A long-term cross-over pharmacokinetic study comparingperphenazine decanoate and haloperidol decanoate in schizophrenicpatients. Pscyhopharmacology 1994; 114: 24-30.55. Kane JM. Schizophrenia. N Engl J Med 1996; 334: 34-41.56. Klein DF, Davis JM. Diagnosis and drug treatment of psychiatricdisorders. Huntington, NY: Krieger, 1969.